• B.Sc. in Biophysical Chemistry, Case Western Reserve University.  PhD in Physiology, Trinity College, University of Cambridge, UK.
• Led medical research group in Cambridge for 20 years.
• Founder of Life Science Resources, divested to Perkin Elmer following three key acquisitions, financing and revenue/profit growth.
• NXC/NXD of a portfolio of healthcare and life science businesses, private and public with experience of IPOs and VC funding.
• Experience of more than 50 healthcare transactions including divestment, M&A, licensing, funding, business development, strategic partnering.

To read a full biography of Dr. Bill Mason, please click here.

• B.S. in Business Management from Long Island University and M.B.A. from Columbia University.
• Founder, President and CEO of Fritzsche, Pambianchi & Associates and Owen, Pambianchi & Associates.
• Co-founder  of The Immune Response Corporation, Cortex Pharmaceuticals and Odyssey Nutriceutical Sciences.
• Founder of The Medical Business Publishing Corporation.
   

For a full biography of Wayne Pambianchi, please click here!

• B.S. in Chemistry from Washington & Lee University, M.B.A. from the Amos Tuck School of Business Administration, Dartmouth College.
• President and Chief Executive Officer of OncoTherapeutics.
• President and CEO of Immunetech Pharmaceuticals (Dura), Inc., of San Diego.
• Director of Marketing, Gynecological Products, at G.D. Searle, Product Manager at Pfizer Laboratories.
• Founding Vice Chairman of the BCNJ Chairman

For a full biography of Gordon Ramseier, please click here!

• Ph.D. in Immunochemistry from Temple University.
• Senior positions in R&D, Marketing, Technological and Strategic Planning at  Johnson & Johnson.
• Director of Technical Planning at Becton-Dickinson.
• General Manager of the Biomedical Division at New England Nuclear.
• Scientific Advisory Boards of the State University of New York at Stony Brook and the University of Utah.
• Trustee of Federal Trade Commission.

For a full biography of Dr. Dan Tripodi, please click here!

• Princeton University AB in Chemistry, Masters degrees in Chemical Engineering and Industrial Management from MIT
• President and Chief Operating Officer, Hemispherx BioPharma
• Vice President, Business Development at Enzon Inc
• Founder and Chief Executive Officer at i-STAT Corporation
• Vice President of Engelhard Industries
• Vice President and General Manager at Halcon International

For a full biography of Doug Hulse, please click here!

• Fordham University, degree in Pharmacy and Iona College, MBA
• President and CEO of Osteologix, 2004 until 2007, Questcor, 1999 until 2004 and RiboGene, 1993 until 1999
• Co-founded in 1989, took public and was CEO of Interneuron (Indevus)
• Held marketing, sales, finance and business development positions with Sandoz, Hoffmann-LaRoche and Johnson & Johnson
• Vice President of Business Development and Strategic Planning for the Critical Care Division for and American Hospital Supply Corporation
• Senior Vice President & General Manager for Pharmaceuticals and Biochemicals at Genzyme from 1985 through 1989
• Four Biotech company IPOs

For a full biography of Charles Casamento, please click here!

Dr. Laurence Shaw, M.D. heads Sage Israel. He is a seasoned and experienced executive in the Life Science industry, and over the last five years has been based in Israel providing consulting services to Israel’s rapidly growing life science startup industry. He currently chairs several  boards of directors. Highlights of this career include roles as Vice President of Abbott Laboratories, Inc., at its corporate headquarters in Chicago, Illinois where he was responsible for advanced research as well as medical and regulatory affairs for its $2 billion revenue Hospital Products Division; Corporate Vice President of Research and Development at C. R. Bard, Inc., an international multi-billion dollar revenue medical device company headquartered in New Jersey, USA; Board member and Director of Medical & Technical Affairs for Revlon Health Care at its European facility. Revlon Health Care was a diversified pharmaceutical company, subsequently acquired by Rorer Pharmaceuticals. Lawrence was also Founder and Chief Executive Officer of Manhattan Pharmaceuticals, a NASDAQ listed company. He has played key startup leadership roles as Chief Executive Officer and President in Pacific Pharmaceuticals Inc. & Applied Spectral Imaging Ltd.

Dr. Tom Geimer heads Sage Australia, He has an honors degree in molecular biology and a PhD in veterinary science from University of Wisconsin at Madison. He also holds a certification in veterinary anesthesiology from the Cornell University and an MBA from London Business School, where he was an international Rotary Scholar. Dr. Geimer has held positions in various start-ups, corporate management in Germany and on the stock market in the city of London. Tom was christened into life sciences in the early days in Europe. Moving from corporate finance into private equity, he has a vast network of contemporary relationships throughout the brokerage and banking sectors. Tom joined Heidelberg Innovations (HI) in 2005 after five years as a Senior Partner with Apax Partners Private Equity and as a private Advisor to HI. Tom was involved with several of the larger transactions at Apax including three corporate spin-outs. In addition, his extensive network resulted in his securing several proprietary deals for Apax including Wilex and Atugen. Tom acted as the primary team member on Genmab which returned over 500% IRR and is one of, if not, the top ranking healthcare transaction in the 25 year history of Apax. In 2008, Tom emigrated to Australia where he runs his corporate finance practice. He maintains strong US and European links. He joined The Sage Group in 2009.

• Heads Sage Japan
• 40 years experience in the healthcare industry
• Managing Director, International as well as Managing Director, Marketing & Sales and Managing Director, R&D Planning for Tsumura & Company from 1993 to 2000
• From 1989 to 1993 he was Vice President, Marketing and Sales, for Searle Yakuhin Company
• From 1988 to 1989 he was Vice President, Business Development Japan for Monsanto/G.D. Searle
• From 1964 to 1988 filled several positions in Ono Pharmaceuticals, covering Project Coordination, Business Development & Licensing, Marketing and Accounting & Finance. 
•  B.A. in Business Administration from Rikkyo University in Tokyo and attended UCLA Graduate School of Management in Medical Marketing  

For a full biography of Yoshi Mizuta, please click here!

Robert Nance, Senior Director, has more than twenty-five years of experience in pharmaceuticals, diagnostics and consumer products.

Mr. Nance has served in various management and executive positions in sales, marketing, and strategic planning for healthcare companies including The Upjohn Company, Beckman Instruments and American Diagnostics Corporation. Mr. Nance has also worked with several start-up ventures.

For the last fifteen years, he has provided private contract services to companies in the pharmaceutical, biotechnology, diagnostics, and consumer products industries, developing specialized marketing and promotional programs. These programs have involved direct to consumer marketing, promotions, seminar/group interactions, peer influence marketing and market research.

Mr. Nance earned a B.S. degree in Biology and Chemistry at The University of Redlands, as well as completing graduate-level work in Neuro-Pathology.
 

Satish K. Tyagi, Senior Director, is a Principal in Delta Capital & Research (DC&R), based in Boston. DC&R provides financial advisory and strategic consulting services for start-up and growth companies in the healthcare information and medical technology field. Typical engagements include seed capital and private placement support, product line analysis, market research, and operations management in conjunction with financing strategy, partnering and M&A counsel. Mr. Tyagi takes an active role in DC&R's venture capital portfolio; recent successful exits include MarketRx, a prescription data analytics business, and Synarc, a radiology CRO.

Mr. Tyagi is also currently engaged as an Advisor with Cornerstone Partners, a healthcare IT M&A boutique serving clients in the United States, Europe and Asia. He currently sits on the Board of Heartland Information Systems, a medical transcription services provider, and has previously served on a number of Boards of public and private companies.

Mr. Tyagi's career spans over two decades in Wall Street research and venture capital. He pioneered investment coverage of healthcare information technology as a unique research sector, during his tenure with Jefferies & Co. and Cowen & Co. Most recently he was with Schroder Ventures (SV Life Sciences II & III) as a Venture Partner. Prior to joining Wall Street, he was a Senior Financial Analyst with The Sage Group. He began his career in Sales & Marketing in 1977 with India's IT pioneer, HCL.

Mr. Tyagi received his B.A. in Economics from University of Delhi, a Post-Graduate Diploma in Marketing from Indian Institute of Management, Calcutta, and M.B.A. in Finance from Stern School, New York University.

Dr Catherine Beech M.B., Ch.B. OBE is medically qualified, with degrees from University of Birmingham (UK) Medical School. She has a strong background in early stage venture capital, with multinational pharmaceutical industry experience both in Europe and the USA. She has expertise in founding, growing and exiting biotechnology and life science businesses. Catherine was awarded the Order of the British Empire (OBE) in the Queen’s Birthday HonoursHonors in June 2008 for services to innovation and technology. She is a Member of the UK Society of Investment Professionals. Catherine has previously worked as Director for Medical Affairs UK for Farmitalia Carlo Erba and Senior Director Medical Affairs, Europe, for DuPont Pharmaceuticals. Subsequent to this, she was a Founder of the Cambridge Gateway Fund, a UK-based venture capital fund where she led the healthcare team in a number of investments and was an investment adviser approved by the UK Financial Services Authority. She has sat on numerous Boards of early stage healthcare companies. More recently, she was Chief Executive of Aitua, a private investment company specialisingspecializing in the commercialisationcommercialization of intellectual property in the life science sector. She has also served as a Member of the UK Department of Trade and Industry’s Technology Strategy Board.

Glenn Kazo has over 20 years of experience in the biopharmaceutical and medical device industries as an industry leader, senior executive, corporate officer and scientist with extensive business development, strategic planning, marketing and financing experience in the global health arena. He has been responsible for raising over $250M in capital from international investors, including a leading role in 3 successful IPOs. He was a founding member of Enzon, Inc., a pioneering drug delivery company who developed Pegylation technology, based on Mr. Kazo's thesis work. While at Enzon, he built and managed a significant business development and licensing group and as VP Sales and Marketing, launched the company's first two products. Subsequently, Glenn joined Focal, Inc. (now a unit of Genzyme Corporation) as Vice President Corporate Development, and helped take this biomaterials company public in 1997. Glenn Kazo became Chief Business Officer, US General Manager, and Board member at XTL Biopharmaceuticals, Inc., an Israeli based research company focusing on infectious disease. At XTL, in addition to establishing its US operations and helping take the company public on the London Stock Exchange, Glenn established a series of licenses and collaborations with leading biopharmaceutical companies in the hepatitis field. Most recently Glenn was Chief Business Officer at Activbiotics, Inc., a private VC backed anti-infective company. He has served on the Board of Directors of XTL, Prolong Pharmaceuticals, a development stage biogeneric pharmaceutical company, and iviGene corporation, now a unit of Oragenics, Inc.

Mr. Cekoric has over 25 years of experience in healthcare with senior management positions in diagnostics, biotechnology, and medical devices. Most recently, Mr. Cekoric served as President of Applied Optronics Corporation, a manufacturer of semiconductor laser devices and systems for use in research, industrial, military, and medical applications. Medical applications included instruments for general surgery, aesthetic laser surgery and photodynamic cancer therapy

Prior to joining Applied Optronics, Mr. Cekoric was President/CEO of Zynaxis, Inc. a biotechnology company engaged in the development of drug delivery products and diagnostic instruments. He took the company through an IPO and raised over $23 million in addition to developing a multimillion dollar collaborative R&D agreement with Eli Lilly in the field of vascular disease.

Previously, he was President of the API Microbiology and Oxford Labware Divisions of Sherwood/American Home Products. API was a $25 million company engaged in the manufacture and sale of diagnostic microbiology systems. Oxford Labware is a $15 million company producing laboratory products such as liquid handling systems, chemistry reagents and coagulation instruments.

He has held senior management positions as President of Hotpack, a manufacturer of clinical laboratory equipment, Vice President/General Manager of Gelman Sciences, a manufacturer of filtration products and analytical instruments, Vice President of Sales and Marketing of the BBL Division of Becton Dickinson, as well as Marketing and R&D positions with Roche Diagnostics.

Mr. Cekoric received his B.S. in Microbiology from Wagner College, his M.S. in Biology from Long Island University, and his Masters Degree in Business from Fordham University. He currently serves on the Technical Advisory Board of the New Jersey Economic Development Authority.

Dr. Burd has dedicated his career to researching and developing novel medical testing products, and to successfully bringing them to market. He is a founder and is currently the President & CEO of Oculir, Inc., developing a non-invasive glucose testing system for people with diabetes. In addition, Dr. Burd is CEO of ImmuneTech, makers of MyAllergyTest, a home test for allergies. Previously, Dr. Burd was a General partner of Windamere Venture Partners, a Venture Fund specializing in founding and funding healthcare companies.

While at Windamere from 1999 to 2003, he and his 2 partners founded 15 healthcare companies. These companies included MiraMedica, Inc., where Dr. Burd served as Chairman and CEO, which developed computer aided detection systems for cancer detection. Founded in 2000, MiraMedica was sold to Kodak in 2003. In addition, in 1999, Dr. Burd founded DexCom, Inc and served as President & CEO. DexCom, Inc., is developing a long-tem implantable glucose sensor for continuous glucose monitoring.

Before DexCom, Dr. Burd was the founder, President/CEO and Chairman of LXN Corporation. Dr. Burd directed the company's work to finance, develop, manufacture, and market a new diabetes self-management system. Johnson and Johnson purchased LXN in 2001. Prior to LXN, Dr. Burd held executive positions at QUIDEL Corporation, including Vice President of Research and Development, where he directed the development of products for the clinical lab, physician's office and OTC markets.

Prior to QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. Dr. Burd began his career in medical product research and development at Bayer (formerly Miles Laboratories, Inc.)

Dr. Burd has authored and co-authored numerous scientific articles and is the owner of 23 U.S. patents. He holds a Bachelor of Science Degree in Biochemistry from Purdue and earned an M.S. and Ph.D. in Biochemistry from the University of Wisconsin.

Peter Levitch is a world-renowned expert in FDA regulations. Mr. Levitch has held senior positions managing the regulatory and clinical programs at Ortho Diagnostic Systems (a subsidiary of Johnson & Johnson) and has been an advisor to more than 200 leading biotechnology and biological firms, including: Amgen, Genentech, Immunex, DuPont, Baxter, J&J.

Mr. Levitch's experience and familiarity with FDA related issues is a key asset to The Sage Group enabling him to accomplish capital conserving yet commercially efficient regulatory strategies and tactical programs. Mr. Levitch, in his years of activity in the health care field, especially in qualifying biotechnology derived products, will provide for The Sage Group what he has so successfully provided for other companies. The sales of the products so successfully assisted by Mr. Levitch have annual sales in the billions of dollars.

Dr. Horovitz was most recently Vice President, Business Development and Planning, Bristol-Myers Squibb. Prior to this assignment, he was involved in various positions which included research and administration. He has successfully consummated several acquisitions for BMS, as well as aligned BMS with meaningful strategic partners. He is currently serving on the board of Synaptic Corp., Avigen Corp., Phyton, Inc., Vivante International, Biocryst Pharmaceuticals, Diacrin, Inc., Procept Corp., InfoMed Holdings, Inc., and Nitromed.

Robert Nakamura is currently Chairman Emeritus and Senior consultant, Department of Pathology, Scripps Clinic and Research Foundation, as well as a Clinical Member, Department of Molecular and Experimental Medicine. Previously, he was President, Scripps Clinic Medical Group, Inc. Dr. Nakamura is highly regarded in the field of diagnostic medicine and has been involved with numerous commercial endeavors.

Dr. Shenk is currently the Enkins Professor of Molecular Biology and Chairman of the Department of Molecular Biology at Princeton University. He is also an investigator at the Howard Hughes Medical Institute. Dr. Shenk is a member of the Board of Directors and Scientific Advisory Board of Novalon Pharmaceutical Corporation.

Dr. Gocke is one of the leading scientists that combining a career in basic and clinical research. During his career, he has been in the forefront of hepatitis diagnosis, HIV detection, infectious disease testing, immunology, and internal medicine. He was the first Dean of the Medical School of New Jersey, which is now called University of Medicine and Dentistry of New Jersey (UMDNJ).